Agarwala SS, Neuberg D, Park Y, Kirkwood JM (2004) Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): a trial of the Eastern Oncology Group. Cancer 100:1692–1698
Aranda F, Vacchelli E, Obrist F, Eggermont A, Galon J, Sautes-Fridman C, Cremer I, Henrik Ter Meulen J, Zitvogel L et al (2014) Trial watch: toll-like receptor agonists in oncological indications. Oncoimmunology 3:e29179
Benvenuti F (2016) The dendritic cell synapse: a life dedicated to T cell activation. Front Immunol 7:70
Chang LS, Leng CH, Yeh YC, Wu CC, Chen HW, Huang HM, Liu SJ (2014) Toll-like receptor 9 agonist enhances anti-tumor immunity and inhibits tumor-associated immunosuppressive cells numbers in a mouse cervical cancer model following recombinant lipoprotein therapy. Mol Cancer 13:60
Fernandez S, Palmer DR, Simmons M, Sun P, Bisbing J, McClain S, Mani S, Burgess T, Gunther V, Sun W (2007) Potential role for Toll-like receptor 4 in mediating Escherichia coli maltose-binding protein activation of dendritic cells. Infect Immun 75:1359–1363
Franklin C, Livingstone E, Roesch A, Schilling B, Schadendorf D (2017) Immunotherapy in melanoma: Recent advances and future directions. Eur J Surg Oncol 43:604–611
Fu HW (2014) Helicobacter pylori neutrophil-activating protein: From molecular pathogenesis to clinical applications. World J Gastroenterol 20:5294–5301
Gajewski TF, Schreiber H, Fu YX (2013) Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol 14:1014–1022
Hong X, Dong T, Hu J, Yi T, Li W, Zhang Z, Lin S, Niu W (2013) Synergistical toll-like receptors activated dendritic cells induce antitumor effects against carcinoembryonic antigen-expressing colon cancer. Int J Colorectal Dis 28:25–33
Huen AO, Rook AH (2014) Toll receptor agonist therapy of skin cancer and cutaneous T-cell lymphoma. Curr Opin Oncol 26:237–244
Iribarren K, Bloy N, Buque A, Cremer I, Eggermont A, Fridman WH, Fucikova J, Galon J, Spisek R et al (2016) Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy. Oncoimmunology 5:e1088631
Kang QZ, Duan GC, Fan QT, Xi YL (2005) Fusion expression of Helicobacter pylori neutrophil-activating protein in E.coli. World J Gastroenterol 11:454–456
Kidner TB, Morton DL, Lee DJ, Hoban M, Foshag LJ, Turner RR, Faries MB (2012) Combined intralesional Bacille Calmette-Guerin (BCG) and topical imiquimod for in-transit melanoma. J Immunother 35:716–720
Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25:402–408
Martorelli D, Muraro E, Merlo A, Turrini R, Rosato A, Dolcetti R (2010) Role of CD4+ cytotoxic T lymphocytes in the control of viral diseases and cancer. Int Rev Immunol 29:371–402
Mempel TR, Bauer CA (2009) Intravital imaging of CD8+ T cell function in cancer. Clin Exp Metastasis 26:311–327
Mikulandra M, Pavelic J, Glavan TM (2017) Recent findings on the application of toll-like receptors agonists in cancer therapy. Curr Med Chem 24:2011–2032
Narayan R, Nguyen H, Bentow JJ, Moy L, Lee DK, Greger S, Haskell J, Vanchinathan V, Chang PL et al (2012) Immunomodulation by imiquimod in patients with high-risk primary melanoma. J Invest Dermatol 132:163–169
Redelman-Sidi G, Glickman MS, Bochner BH (2014) The mechanism of action of BCG therapy for bladder cancer–a current perspective. Nat Rev Urol 11:153–162
Riggs P (2000) Expression and purification of recombinant proteins by fusion to maltose-binding protein. Mol Biotechnol 15:51–63
Rodriguez-Cerdeira C, Carnero Gregorio M, Lopez-Barcenas A, Sanchez-Blanco E, Sanchez-Blanco B, Fabbrocini G, Bardhi B, Sinani A, Guzman RA (2017) Advances in Immunotherapy for Melanoma: a comprehensive review. Mediators Inflamm 2017:3264217
Sanlorenzo M, Vujic I, Posch C, Dajee A, Yen A, Kim S, Ashworth M, Rosenblum MD, Algazi A et al (2014) Melanoma immunotherapy. Cancer Biol Ther 15:665–674
Schadendorf D, van Akkooi ACJ, Berking C, Griewank KG, Gutzmer R, Hauschild A, Stang A, Roesch A, Ugurel S (2018) Melanoma Lancet 392:971–984
Siegel RL, Miller KD, Jemal A (2019) Cancer statistics, 2019. CA Cancer J Clin 69:7–34
Sisti A, Sisti G, Oranges CM (2014) Topical treatment of melanoma skin metastases with imiquimod: a review. Dermatol Online J 21:14
Smith M, Garcia-Martinez E, Pitter MR, Fucikova J, Spisek R, Zitvogel L, Kroemer G, Galluzzi L (2018) Trial Watch: Toll-like receptor agonists in cancer immunotherapy. Oncoimmunology 7:e1526250
Vacchelli E, Eggermont A, Sautes-Fridman C, Galon J, Zitvogel L, Kroemer G, Galluzzi L (2013) Trial Watch: Toll-like receptor agonists for cancer therapy. Oncoimmunology 2:e25238
Vacchelli E, Galluzzi L, Eggermont A, Fridman WH, Galon J, Sautes-Fridman C, Tartour E, Zitvogel L, Kroemer G (2012) Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy. Oncoimmunology 1:894–907
Wahl RU, Braunschweig T, Ghassemi A, Rubben A (2016) Immunotherapy with imiquimod and interferon alfa for metastasized Merkel cell carcinoma. Curr Oncol 23:e150–e153
Wang T, Liu X, Ji Z, Men Y, Du M, Ding C, Wu Y, Liu X, Kang Q (2015) Antitumor and immunomodulatory effects of recombinant fusion protein rMBP-NAP through TLR-2 dependent mechanism in tumor bearing mice. Int Immunopharmacol 29:876–883
Weigelin B, Krause M, Friedl P (2011) Cytotoxic T lymphocyte migration and effector function in the tumor microenvironment. Immunol Lett 138:19–21
Yang H, Wang B, Wang T, Xu L, He C, Wen H, Yan J, Su H, Zhu X (2014) Toll-like receptor 4 prompts human breast cancer cells invasiveness via lipopolysaccharide stimulation and is overexpressed in patients with lymph node metastasis. PLoS ONE 9:e109980
留言 (0)